What Is XTMAB-16?
An Investigational New Drug (IND) candidate being developed by Xentria to suppress the physiologic response to tumor necrosis factor.
What Medical Condition Does It Target?
Sarcoidosis - A rare inflammatory disease that interferes with an organ’s structure and function.
What Happens?
Sarcoidosis is characterized by the formation of granulomas—tiny clumps of inflammatory cells—in one or more organ of the body.
- Lungs are involved in approximately 90% of cases
- Almost any organ can be affected by this rare disease
- When left untreated, inflammation can lead to fibrosis which is permanent scarring of the organ tissue
Key Points
- Spontaneous disease resolution can occur within 12-36 months of symptom onset
- Severe cases of progressive disease can become advanced and chronic in approximately 25% of cases
- Organ inflammation or fibrosis can cause many physical and psychological symptoms
What We Know
- Sarcoidosis is a rare inflammatory disease that interferes with an organ’s structure and function.
- Sarcoidosis is characterized by the formation of granulomas—tiny clumps of inflammatory cells—in one or more organ of the body.
- The exact cause of sarcoidosis is unknown, researchers continue to explore genetic, seasonal and occupational influences.
Symptoms
of cases the lungs are involved.
of patients have eye symptoms.
of patients develop a skin symptom.
of patients have heart-related symptoms.
Treatment
- Treatment for this disease is often started to resolve symptoms or prevent disease progression.
- If you do require treatment, it is important to work with your medical doctor to explore the treatment decision that works best for you.
A disease of unknowns...
Awareness
Since sarcoidosis is rare and symptoms vary widely, people can go for years without knowing they have it.
Diagnosis
There are no definitive tests or biomarkers, so it may take many doctor’s visits to rule out other options before receiving a diagnosis.
Management
Most doctors have almost no training on sarcoidosis and lack the tools to manage treatment effectively over time. The measures that do exist don’t capture what’s most meaningful for patients, like fatigue or ability to work.
While the exact causes of sarcoidosis are unknown, research suggests that inflammatory pathways are likely a driving force. We are working to better understand these pathways and find promising targets for future medicines, which could redefine the standard of care.
Additional Resources
Xentria is partnered with the Foundation for Sarcoidosis Research (FSR)
(Additional information for patients and caregivers looking to connect with others facing this disease.)
Sarcoidosis Snapshot
(Disease Overview)